After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a path forward ...

-- PanGIA Analysis System, a novel machine learning platform for non-invasive diagnosis of oral cancer through an oral sample -- PanGIA Analysis System, a novel machine learning platform for ...

Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...

Praxis, a top biotech stock, surged Tuesday after the FDA assigned a potential approval date for its essential tremor ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

Biogen could see lower royalties for Ocrevus after its patent expires , but it has developed other medicines that will ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

Mantis takes disparate sources of data to make synthetic datasets that can be used to build so-called "digital twins" of the human body, representing anatomy, physiology and behavior.

The threat of new tariffs on drugmakers has set off a debate within the biotech industry over whether to cut voluntary pricing deals with the Trump administration in exchange for exemptions. Why it ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...